FDA Approves Journavx: First Non-Opioid Painkiller for Severe Pain in Over 20 Years

In what medical experts are calling a watershed moment in pain management, the U.S. Food and Drug Administration approved Journavx (suzetrigine) in January 2025 — the first entirely new class of non-opioid painkiller approved for moderate-to-severe acute pain in more than two decades. Developed by Vertex Pharmaceuticals, the drug represents a fundamental breakthrough in addressing pain without the devastating addiction risks associated with opioids.

Suzetrigine works through an entirely novel mechanism. Rather than targeting the brain's opioid receptors — which provides pain relief but also triggers the euphoria and dependency that fuel addiction — Journavx blocks a specific sodium channel called NaV1.8 found primarily in pain-sensing nerves. By selectively inhibiting these channels, the drug prevents pain signals from reaching the brain while leaving other neural functions unaffected.

“S.”

The FDA granted the drug priority review, fast track, and breakthrough therapy designations, reflecting the urgency of finding alternatives to opioids amid an addiction crisis that has claimed hundreds of thousands of lives. Clinical trials demonstrated that suzetrigine provided pain relief comparable to opioid-based medications following surgical procedures, including abdominoplasty and bunionectomy.

Critically, Journavx showed no evidence of the addictive properties that make opioids so dangerous. Patients in trials did not develop tolerance, physical dependence, or drug-seeking behavior — issues that have plagued opioid prescriptions for decades. The drug's side effect profile was also favorable, with fewer gastrointestinal issues than traditional pain medications.

The approval opens the door for a fundamental shift in how acute pain is managed in hospitals, surgical centers, and emergency departments across the country. For millions of patients who undergo surgery each year, Journavx offers the possibility of effective pain management without the shadow of potential addiction.

Experts note that while suzetrigine is initially approved for acute pain, research is ongoing into its potential for treating chronic pain conditions, which could further reduce reliance on long-term opioid prescriptions. The drug's success also validates the NaV1.8 channel as a therapeutic target, potentially spurring development of additional non-opioid pain medications.